These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 32468013)

  • 1. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
    Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
    Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
    Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Lea J; Panwar V; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2024 Aug; 37(8):100532. PubMed ID: 38848896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes.
    Xu L; Pelosof L; Wang R; McFarland HI; Wu WW; Phue JN; Lee CT; Shen RF; Juhl H; Wu LH; Alterovitz WL; Petricon E; Rosenberg AS
    Front Immunol; 2020; 11():224. PubMed ID: 32265897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
    Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
    Front Immunol; 2021; 12():778329. PubMed ID: 34975867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
    Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients.
    Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Abu Nada M; Elkord E
    Epigenomics; 2020 Nov; 12(21):1871-1882. PubMed ID: 33169618
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.
    Narayanan S; Kawaguchi T; Peng X; Qi Q; Liu S; Yan L; Takabe K
    Sci Rep; 2019 Sep; 9(1):13455. PubMed ID: 31530839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of immune checkpoint molecules in breast cancer.
    Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.